Health and Healthcare
Mixed Short Interest in Drug & Medical Stocks (June 2007)
Published:
As you will see, the short interest changes in medical and drug stocks of the active NYSE-listed names was a bit of a mixed bag. GlaxoSmithkline (GSK) saw the lagest increase, but its short interest is not representative of its real size or activity because it is an ADR and less active here compared to U.K. trade volume. We ranked hese in terms of percentages with the largest increase in short interest first.
STOCK (Ticker) JUNE07 MAY07 Change
GlaxoSmithkline (GSK) 7.74M 4.15M +86%
Boston Scientific (BSX) 32.07M 24.06M +33.3%
Wyeth (WYE) 3.3M 10.37M +28.3%
Labcorp (LH) 4.11M 3.21M +28%
Bristol-Myers (BMY) 26.95M 23.85M +13%
Schering-Plough (SGP) 16.79M 15.27M +9.9%
Medtronic (MDT) 16.11M 15.19M +6%
Pfizer (PFE) 54.48M 52.12M +4.5%
Quest Diagnost. (DGX) 18.00M 17.54M +2.6%
Merck (MRK) 22.82M 22.55M +1.2%
Eli Lilly (LLY) 13.77M 14.07M -2.1%
J&J (JNJ) 15.37M 16.16M -4.9%
Zimmer Holdings (ZMH) 3.89M 4.13M -5.8%
St. Jude MEdical (STJ) 6.53M 7.13M -8.4%
Genentech (DNA) 6.87M 8.16M -15.9%
Abbott Labs (ABT) 11.74M 16.39M -28.3%
Jon C. Ogg
June 24, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.